![]() ![]() Where can you find these cards? Look for them at Buehler’s, Giant Eagle, Kmart, Lowe’s, Office Depot/OfficeMax, Safeway, SuperValu, Toys R Us and Wegmans. ![]() But for now, they’re getting this operation off the ground by just offering a little less than 2 dozen choices: Coca-Cola Co. Stockpile will eventually offer stock from hundreds of companies. Pick up a few bags of chips…and some stock! Trodelvy, by comparison, could hit a peak of $2 billion in sales.What do you get when you cross the world of gift cards with directly owning fractional shares of stocks? Stockpile Inc., a startup that will be selling shares of your favorite companies alongside gift cards at locations like grocery stores just in time for holiday shoppers. At its peak, the therapy could bring in up to $1.5 billion in annual revenue. Gilead also obtained FDA approval last year for Sunlenca, a twice-yearly injectable for people with multi-drug-resistant HIV. Analysts project it can bring in $955 million in sales this year (up from $680 million in 2022). Food and Drug Administration (FDA) to treat patients with an advanced form of breast cancer (HR-positive/HER-negative). The company already has some exciting growth catalysts in the works with its breast cancer drug Trodelvy obtaining approval from the U.S. ![]() By diversifying its product mix and strengthening its pipeline, the business will make for a better long-term investment. In oncology alone, there are dozens of trials ongoing that could help further diversify the company's operations.Ĭurrently, Gilead's business centers around its HIV treatments, which accounted for 63% of the $27.3 billion in revenue it reported last year. That cash can help the business expand as Gilead has 59 clinical-stage programs in its pipeline. The company pays out less than $4 billion in dividends on an annual basis, so there's plenty left over after paying shareholders a generous 3.5% yield to invest money back into the business. Last year, it brought in $8.3 billion in free cash flow, which was down from $10.8 billion the previous year. Gilead Sciences fits that category as the company routinely generates operating profits and brings in free cash flow to not only support its dividend, but also to help grow its business. Plenty of cash to pay dividends and fund growthĭavid Jagielski (Gilead Sciences): A company that's flush with cash is one that will always have growth opportunities to pursue. And with its solid dividend profile and a very conservative cash payout ratio of 41%, AbbVie remains a top pick for investors looking for a cash cow, be it for passive income or otherwise. That's the most important thing if the company is to continue rewarding shareholders with payout increases. There will be many more going forward.Įven with the end of the Humira era, AbbVie can continue delivering solid and increasing revenue and earnings. AbbVie expects roughly 10 approvals or regulatory submissions this year. The sheer breadth and diversity of AbbVie's portfolio is a strength, especially as it is more than capable of earning new approvals regularly. In addition to its immunology focus, the company is also active in oncology, neuroscience, eye disease, and aesthetics. AbbVie's product lineup is more diversified than ever. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |